Drugs / Recombinant human activated coagulation factor VIII
Recombinant human activated coagulation factor VIII
also known as
Recombinant human coagulation factor VIII
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06297655 | Nov 2024 → Jul 2026 overdue | hemophilia A | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human activated coagulation factor VIII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06297655 ↗ |
| Known as | Recombinant human coagulation factor VIII | “Recombinant human coagulation factor VIII for injection is a recombinant DNA product with functional characteristics comparable to endogenous factor VIII.” NCT06297655 ↗ |
| Action | Restore | “as a replacement therapy for severe hemophilia A PTPs during the perioperative period” NCT06297655 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human coagulation factor VIII for injection is a recombinant DNA product” NCT06297655 ↗ |